Neovasc Inc (US)(NASDAQ:NVCN) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 23, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $2.761M. Analysts estimated a revenue of $2.630M. The revenues were 4.98% above the estimates. Earnings per share were $-0.32. The reported EPS was below estimates by -255.56%. Analysts had estimated an EPS of $-0.09.
Neovasc Inc (US) (NVCN) shares turned negative on Fridays trading session with the shares closing down -0.16 points or -9.52% at a volume of 52,15,597. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.04. The peak price level was also seen at $2.04 while the days lowest was $1.5. Finally the shares closed at $1.52. The 52-week high of the shares is $4.4 while the 52-week low is $0.37. According to the latest information available, the market cap of the company is $120 M.
Neovasc Inc. is a specialty medical device company. The Company develops manufactures and markets products for the cardiovascular marketplace. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease the Reducer for the treatment of refractory angina and a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. Its Tiara is a product for treating mitral valve disease. The Tiara is in preclinical/early clinical stage development to provide an invasive transcatheter device. The Tiara valve is made up of two components: the leaflets and skirt. It produces Peripatch a biological tissue product that is manufactured from pericardium which is the protective sac that surrounds the heart of an animal. It provides product development and specialized manufacturing services related to Peripatch tissue-based products.